In this free webinar, gain insights into how reducing the duration of cell culture process development is crucial in biopharmaceutical development. Attendees will learn how the high-throughput (HTP) parallel bioreactor systems allow extensive design of experiment (DOE) exploration. The featured speaker will discuss how the generation of reproducible and scalable data under automated process control facilitates the tech transfer process and more.
TORONTO, Oct. 2, 2023 /PRNewswire-PRWeb/ -- The production of biologics typically centers around the upstream process development stage involving the use of Chinese hamster ovary (CHO) cells in a bioreactor. It is necessary to implement a dependable tech transfer method from development to manufacturing scale.
Finding ways to optimize the cost of goods with higher yield and enhanced quality is crucial for ensuring long-term commercial viability. Historically, shake flasks with benchtop bioreactors have been employed for screening and characterizing methods in the early stages of upstream development. However, the increasing interest is focused on the application of high-throughput (HTP) single-use technologies to expedite tech transfer and minimize resource utilization.
Ambr® 250 high-throughput 24-way bioreactor system integrated with the MODDE DOE software and bioanalyzers can be used at different stages of upstream development and upstream process optimization. Upstream process development, especially testing media, screening feeding strategy and characterizing operating conditions is performed using the resource-efficient tool.
The application of bioreactor vessels with similar geometry and aspect ratio is encouraged to simplify the scaling process between bioreactors. The identification of potential critical process parameters using multi-parallel bioreactors is followed by the definition of acceptable operation ranges. The qualifying mini-scale systems are also used as the scale-down model to mimic the process at larger scales and determine the design space based on the rich statistically relevant data. The generation of reproducible and scalable data shortens the tech transfer timeline for accelerated delivery of products to patients.
Join this webinar where Dr. Ali Abghari will discuss the importance of upstream process development in elevating titer and quality, as well as achieving a robust, scalable process.
Join Ali Abghari, PhD, Senior Scientist, Aragen, for the live webinar on Wednesday, October 11, 2023, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Upstream Process Development for Better Yield and Product Quality.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]
SOURCE Xtalks
Share this article